During the previous funding period, the pharmacology core laboratory has supported all three projects, providing measurement of more than a dozen different anticancer drugs. In the previous application the specific aims outlined pharmacology studies with hexamethylene bisacetamide; leucovorin, 5 fluorouracil, and 5 fluoro-2'-deoxyuridine; lometrexol; chloroquinoxaline sulfonamide(CQS), and trimetrexate. Each of these assays was developed and pharmacology studies completed. The analytical laboratory performed drug concentration analysis on more than 2000 samples annually. The contribution of the pharmacology core to the clinical development of all trans retinoic acid, suramin, and CQS have been particularly important.
The specific aims for the pharmacology core laboratory will be: 1. To continue analytical support for ongoing studies of (CQS), edatrexate, taxol, and all trans retinoic acid (ATRA); 2. Assays for phenylacetic acid, phenylbutyric acid and phenyl acetylglutamine; 3. Develop a method for lobaplatin in human body fluids; 4. Develop assays for clinically important retinoids including All trans retinoic acid, 9-cis retinoic acid, 13 cis reinoic acid and novel retinoids proposed in Project 1; 5. Establish a method for measuring the P 450 test substrate, erythromycin, in plasma; 6. Develop a more sensitive HPLC assay which can specifically separate and quantitate antifolates including methotrexate, edatrexate, trimetrexate and newer antifols; 7. To employ capillary electrophoresis to develop a micro assay for methotrexate polyglutamates in small tissue samples.
|Tedeschi, Philip M; Vazquez, Alexei; Kerrigan, John E et al. (2015) Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Mol Cancer Res 13:1361-6|
|Bell, Melanie L; Kenward, Michael G; Fairclough, Diane L et al. (2013) Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346:e8668|
|Zhou, Ping; Hoffman, James; Landau, Heather et al. (2012) Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk 12:49-58|
|Rizvi, Naiyer A; Rusch, Valerie; Pao, William et al. (2011) Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 17:3500-6|
|Zhao, Binsheng; Oxnard, Geoffrey R; Moskowitz, Chaya S et al. (2010) A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-53|
|Klimek, Virginia M; Fircanis, Sophia; Maslak, Peter et al. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826-32|
|Riely, Gregory J; Kris, Mark G; Zhao, Binsheng et al. (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5|
|Zhao, Binsheng; Schwartz, Lawrence H; Moskowitz, Chaya S et al. (2006) Lung cancer: computerized quantification of tumor response--initial results. Radiology 241:892-8|
|Maslak, P; Chanel, S; Camacho, L H et al. (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:212-7|
|Yankeelov, Thomas E; Rooney, William D; Huang, Wei et al. (2005) Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 18:173-85|
Showing the most recent 10 out of 39 publications